Alterity Therapeutics (ASX: ATH) has successfully completed enrollment in its ATH434-201 Phase 2 clinical trial, a randomized, double-blind, placebo-controlled study for early-stage Multiple System Atrophy (MSA). The trial, conducted globally, exceeded its enrollment target, indicating strong interest in the novel approach to MSA treatment. The study, set to conclude in Q4 2024, will assess the impact of ATH434 on neuroimaging and protein biomarkers, safety, and efficacy, including motor activity using wearable sensors.
The study includes 77 participants who received ATH434 or a placebo over 12 months. Alterity's lead candidate, ATH434, aims to inhibit pathological protein aggregation and restore iron balance in the brain. MSA is a debilitating neurodegenerative disease with no current cure, and ATH434 has received Orphan drug designation from the U.S. FDA and the European Commission for MSA treatment. Alterity Therapeutics is dedicated to developing treatments for neurodegenerative diseases, with ATH434 showing promise in treating various Parkinsonian disorders.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
